<DOC>
	<DOCNO>NCT00475826</DOCNO>
	<brief_summary>Study Title : Evaluation chylomicron metabolism sub-clinical atherosclerosis patient whit Heterozigous Familial Hypercholesterolemia ( FH ) treat statin plus ezetimibe . Background : Coronary artery calcification ( CAC ) marker sub-clinical coronary atherosclerosis correlate high risk clinical event . It already demonstrate CAC prevalent patient FH compare normal individual . A number study demonstrate plasmatic removal chylomicron defective patient atherosclerosis . Despite fact still controversial whether impairment occurs patient HF compare normal control , kinetics chylomicron study HF patient without atherosclerosis important , clear change may observe sub-clinical disease , report CAC asymptomatic individual . Previous study demonstrate inverse correlation among LDL-C level removal remnant chylomicron use artificial chylomicron technique . It also well know high dos potent statin effective remove chylomicron plasma due good expression LDL-C receptor plasma LDL-C reduction . It evaluate yet association ezetimibe statin , enhance LDL-C receptor expression liver would enhance efficacy monotherapy statins remove artificial chylomicron patient HF . Study design : Open , randomize , single-blinded study twenty six outpatient Lipids Clinical Unit Heart Institute ( INCOR ) , University SÃ£o Paulo , previously diagnose FH accord US MED PED criterion , without history CD CAC evaluation MSCT ( Multiple Sensors Computed Tomography ) previous year compare 26 control individual match age sex collect database Lipids Metabolism Laboratory . Patients randomize receive simvastatin 40 mg monotherapy combination ezetimibe 10 mg undergoing three kinetics study demonstrate effect simvastatin 40 mg kinetics chylomicron along laboratorial dosage ( lipid fraction , hepatic enzyme CK ) . The primary endpoint study evaluate correlation among reduction plasma clearance chylomicron artificial chylomicron technique presence sub-clinical atherosclerosis ; secondary endpoint evaluate ezetimibe/simvastatin enhance effect simvastatin alone removal chylomicron patient HF .</brief_summary>
	<brief_title>Evaluation Chylomicrons Metabolism Sub-Clinical Atherosclerosis Patients Whit Heterozigous Familial Hypercholesterolemia ( FH ) Treated With Statin Plus Ezetimibe</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Heterozigous Familial Hypercholesterolemia patient Age 18 70 Male Female Coronary artery calcification Coronary artery disease Cerebrovascular disease Diabetes Mellitus Heart Failure Class IIIIV Thyroid disease Peripheral Artery disease Pregnancy , woman without anticonceptive method Kidney disease calcium disturb Thoracic Cancer Use Beta Blockers , diuretic , glucocorticoid , hormone replacement therapy except oral anticonception Use lipid lower drug last six week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Heterozigous Familial Hypercholesterolemia</keyword>
	<keyword>Sub-clinical atherosclerosis</keyword>
	<keyword>Chylomicrons metabolism</keyword>
	<keyword>Statin plus ezetimibe</keyword>
	<keyword>Coronary artery calcification</keyword>
</DOC>